Dear Editor,

The global outbreak of COVID-19 has seriously endangered healthcare systems in China and worldwide. 15.7% of cases of COVID-19 were severe, and 5% were critical according to guidelines on the diagnosis and treatment of new coronavirus pneumonia (version 6) \[[@CR1]\]. One recent study reported that the fatality rate of COVID-19 in China is 1.4% \[[@CR2]\]. Despite showing a lower case fatality rate, COVID-19 has so far resulted in more deaths than SARS and MERS combined \[[@CR3], [@CR4]\]. It is important to establish whether there is a difference between severe and critical patients, as this might help us to identify critical patients in a more timely and effective manner. However, to date, few biomarkers of progression of COVID-19 have been reported.

In this single-center retrospective study, written informed consent was duly obtained from all patients. The study was approved by the Ethics Committee of the first affiliated hospital of Harbin Medical University. A total of 45 COVID-19 patients were included. Our study defined the severity of COVID-19 according to the guidelines on the diagnosis and treatment of new coronavirus pneumonia (version 6). We also attempted to evaluate the severity of COVID-19 patients using the sequential organ failure assessment (SOFA) scoring system.

A logistic regression model was used to analyze the factors influencing the severity of the disease. Among the total of 19 adjustable variables (seen in supplementary data) in the univariate analysis, 3 and 2 significant indicators were found two different evaluation systems, respectively. In addition to using these indicators, comorbidities, age, and sex were also included in the model for multivariate regression analysis.

The patients' baseline characteristics were compared between the severe and the critical group according to the two different evaluation systems. Classification according to version 6 (eTable-1): among 33 severe patients (mean age 63.13 ± 14.1 years), 17 \[52%\] were male; among 12 critical patients mean age (62.58 ± 9.89 years), 6 \[50%\] were male. IL-6 levels (Fig. [1](#Fig1){ref-type="fig"}a) (*p* = 0.0004) and IL-10 levels (eFig. 2) (*p* = 0.0073) were significantly lower in the severe group than in the critical group (eTable 1); the results showed that IL-6 levels (Fig. [1](#Fig1){ref-type="fig"}b, eTable 2--4) were related to the severity of COVID patients (*p* = 0.0121). The AUC of IL-6 was 0.848, the sensitivity 90.91%, the specificity 66.67%, and the cutoff value 19.03 pg/ml. Classification according to the SOFA score system (Severe: SOFA \< 2; Critical: SOFA ≥ 2) (eTable 5): among 14 severe patients (mean age 57.69 ± 19.34 years), 8 \[57%\] were male; among 31 critical patients (mean age 65.19 ± 8.63 years), 15 \[48%\] were male. Lower IL-6 levels (Fig. [1](#Fig1){ref-type="fig"}c) (*p* \< 0.0001) and higher CD3 (eFig. 3) (*p* = 0.0032) were found in the severe group compared with the critical group. The results (see supplementary data) showed that IL-6 levels (Fig. [1](#Fig1){ref-type="fig"}d, eTable 6--8) were related to the severity of COVID patients (*p* = 0.0151). The AUC of IL-6 was 0.910, the sensitivity 85.71%, the specificity 96.77%, and the cutoff value 6.11 pg/ml.

![IL-6 levels (*p* = 0.0004)**a** was significantly lower in severe group than critical group due to Guidelines of the Diagnosis and Treatment of New Coronavirus Pneumonia (version 6), AUC of IL-6 is 0.848, sensitivity is 90.91%, specificity is 66.67% (**b**); IL-6 levels (*p* \< 0.0001),**c** was significantly different in two disease groups due to SOFA scoring system., AUC of IL-6 is 0.910, sensitivity is 85.71%, specificity is 96.77% (**d**)](134_2020_6065_Fig1_HTML){#Fig1}

In conclusion, up-regulated IL-6 levels may serve as a potential marker for predicting progression of COVID-19 patients. Whether evaluated according to the version 6 guidelines or the SOFA score, IL-6 is good at assessing COVID-19 progression.
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